ArticleBMC cancer2026
Comprehensive CYP2D6 genotyping improves phenotype classification and highlights methodological pitfalls in tamoxifen-treated breast cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical utility of CYP2D6 genotyping in predicting tamoxifen outcomes remains controversial, partly due to incomplete allele coverage and limited assessment of copy number variation (CNV). We aimed to expand CYP2D6 genetic profiling in Syrian breast cancer patients and to reassess phenotype classification and its clinical relevance.
methodsIn this retrospective cohort of estrogen receptor-positive breast cancer patients treated with adjuvant tamoxifen, CYP2D6 genotyping was performed using a test strip-based assay complemented by semi-quantitative PCR for CNV detection. Selected results were validated by next-generation sequencing (NGS). Diplotypes were translated into activity scores to assign metabolizer phenotypes. Disease-free survival (DFS) was evaluated using time-to-event analyses.
resultsExpanded CYP2D6 profiling, incorporating broader allele coverage and CNV analysis, led to metabolizer phenotype reclassification in 19% of patients. NGS identified primer-binding region variants responsible for allele drop-out in conventional assays. No significant association between CYP2D6 phenotype and DFS was observed in the overall cohort. However, exploratory stage-specific analyses suggested shorter DFS among patients with reduced CYP2D6 activity in Stage II disease (HR = 3.59; 95% CI 2.34-67.48), although estimates were imprecise due to small subgroup size.
conclusionsComprehensive CYP2D6 profiling improves phenotype assignment and highlights methodological pitfalls that may contribute to inconsistencies in pharmacogenetic studies. While no definitive association with clinical outcomes was observed in the overall cohort, these findings underscore the importance of analytically robust genotyping strategies and warrant validation in larger, prospectively designed cohorts, and highlight the importance of comprehensive genotyping strategies in resolving inconsistencies across pharmacogenetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.